Latest News:

Tufts CSDD Demonstrates Multi-Million-Dollar Benefits of Translational Pharmaceutics®

Downloading our Whitepaper

You are about to download this document, please enter your contact details below to start downloading.

Whitepaper

Accelerating development of enabled formulations for poorly soluble drugs

Efficacy issues due to inadequate gastrointestinal (GI) absorption caused by insufficient aqueous solubility are encountered in up to 70% of new drugs in development.1 Typically, in vitro analysis and preclinical studies are used to predict the behaviour of the drug in vivo

Would you like to receive further scientific content including case studies, whitepapers and seminar and webinar invitations?
You can find out how we handle your personal information in our privacy policy here.

Ask us a question

We use cookies to help us to improve our site and enables us to the best possible service and customer experience. By clicking accept you are agreeing to let us share your data with select third parties for analytics and marketing purposes.